Clinical Advances in

HIV: Optimizing Patient Care

Advances in antiretroviral therapy and HIV care have more than doubled the life expectancy of the more than 1.2 million people in the United States living with HIV. Healthcare providers are now managing HIV as a chronic disease in an aging population with common chronic health conditions. Better treatments as well as advances in HIV prevention are helping to stem the epidemic. This collection provides important information and perspectives on the latest advances in HIV treatment and care.

CME Activities

Polling Question

Related Resources

Downloadable Slide Kit

Updates on Treatment of HIV Infection

Download

Clinical Articles

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Read article

Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Read article

Laboratory Testing for the Diagnosis of HIV Infection Read article

Steering Committee

Richard D. Moore, MD

Steering Committee Chair

Professor of Medicine, Johns Hopkins University, Baltimore, Maryland

Joseph J. Eron, MD

Professor of Medicine, University of North Carolina at Chapel Hill School of Medicine

William David Hardy, MD

Senior Director of Evidence-based Practices, Whitman-Walker Health; Adjunct Professor of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine

Bisola Ojikutu, MD, MPH

Assistant Professor, Harvard Medical School; Associate Physician, Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts

Mark Sulkowski, MD

Professor; Medical Director, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland

Babafemi Taiwo, MBBS

Chief, Division of Infectious Diseases, Northwestern University, Chicago, Illinois

	Which of the following patients with HIV infection would you most likely consider switching from a triple-to a dual-therapy antiretroviral regimen?
		A patient who is suppressed, but is experiencing drug-drug interactions
		A patient who is suppressed, but is experiencing adverse events
		A patient who is suppressed, but cannot adhere to a multitablet regimen
		Any of the above
		None of the above